← Back to Search

Neurostimulation

Neurostimulation for Chronic Pain in Kidney Failure (PRUNE Trial)

N/A
Recruiting
Led By Cary Reid, MD, PhD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients: Age ≥ 21 years
Pain for ≥3 months, with a self-reported pain intensity of ≥4 (on a 0-10 scale) during the week preceding the screening;
Must not have
Patients: Active medical or major psychiatric illnesses that will impact pain or interfere with study procedures
Patients: Not able to respond to brief questionnaires and rating scales that will interfere with study procedures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 weeks (during intervention), 8 weeks (at the end of intervention), 12, 16, and 26 weeks post-baseline.
Awards & highlights

Summary

This trial will test if a battery-powered device that sends electrical stimulation to the head can reduce pain for people who receive hemodialysis.

Who is the study for?
This trial is for English-speaking adults over 21 with chronic pain (intensity ≥4/10) for at least 3 months, who are undergoing hemodialysis for end-stage kidney disease. They must be cognitively able to consent and participate in the study without major psychiatric illnesses or medical conditions that could affect their pain or interfere with the trial.
What is being tested?
The study tests a headband device delivering low-level electrical stimulation (active tDCS) against a sham device to see if it can reduce chronic pain in patients receiving hemodialysis. It's a comparison between an active treatment and a placebo-like control.
What are the potential side effects?
Potential side effects may include discomfort at the site of electrode placement, mild skin irritation on the head, headache, fatigue, or tingling sensations during use of the tDCS device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 21 years old or older.
Select...
I have had pain for over 3 months with a pain level of at least 4 out of 10.
Select...
I have had pain for over 3 months with a pain level of at least 4 out of 10.
Select...
I have end-stage kidney disease and am getting dialysis at a Rogosin site.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any major illnesses or psychiatric conditions that could affect my pain levels or participation.
Select...
I cannot complete short questionnaires or rating scales.
Select...
I have a history of head issues or surgeries that might affect where electrodes are placed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 weeks (during intervention), 8 weeks (at the end of intervention), 12, 16, and 26 weeks post-baseline.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 weeks (during intervention), 8 weeks (at the end of intervention), 12, 16, and 26 weeks post-baseline. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in Depressive Symptoms (Patient Health Questionnaire; PHQ-8)
Change in Pain interference (PROMIS pain interference short form)
Change in Quality of Life Questionnaire Score (WHOQOL-BREF)
+7 more

Side effects data

From 2015 Phase 2 trial • 10 Patients • NCT02514044
90%
Non-significant skin redness and tingling
20%
Mild Headache
10%
Mild Insomnia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo+tDCS+Speech Therapy
D-AMP+tDCS+Speech Therapy

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExperimentalExperimental Treatment1 Intervention
Patients will receive tDCS delivered over the motor cortex, at an intensity of 2mA, delivered for 20 minutes 5 times each week over eight consecutive weeks (40 applications in total).
Group II: Sham ComparatorPlacebo Group1 Intervention
Sham treatment will consist of 30 seconds of the direct current at 2mA and 0 current for the remaining time of the 20-minute application 5 times per week over eight consecutive weeks (40 applications in total).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Active tDCS
2012
Completed Phase 2
~1150

Find a Location

Who is running the clinical trial?

Cornell UniversityOTHER
170 Previous Clinical Trials
14,090,993 Total Patients Enrolled
Metropolitan Jewish Health SystemOTHER
2 Previous Clinical Trials
553 Total Patients Enrolled
Rogosin InstituteUNKNOWN
1 Previous Clinical Trials
643 Total Patients Enrolled

Media Library

Active tDCS (Neurostimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05311956 — N/A
Kidney Failure Research Study Groups: Sham Comparator, Experimental
Kidney Failure Clinical Trial 2023: Active tDCS Highlights & Side Effects. Trial Name: NCT05311956 — N/A
Active tDCS (Neurostimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05311956 — N/A
~38 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top